Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Incyte Corporation employs 1,456 staff and has a trailing 12-month revenue of around USD$2.4 billion.
Since the stock market crash in March caused by coronavirus, Incyte Corporation's share price has had significant positive movement.
Its last market close was USD$85.39, which is 5.27% up on its pre-crash value of USD$80.89 and 36.67% up on the lowest point reached during the March crash when the shares fell as low as USD$62.48.
If you had bought USD$1,000 worth of Incyte Corporation shares at the start of February 2020, those shares would have been worth USD$866.20 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,170.70.
|Latest market close||USD$85.39|
|52-week range||USD$62.48 - USD$110.37|
|50-day moving average||USD$93.935|
|200-day moving average||USD$93.4336|
|Wall St. target price||USD$106.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.871|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-11)||N/A|
|1 month (2020-08-18)||N/A|
|3 months (2020-06-22)||-21.61%|
|6 months (2020-03-18)||N/A|
|1 year (2019-09-18)||N/A|
|2 years (2018-09-18)||N/A|
|3 years (2017-09-18)||N/A|
|5 years (2015-09-18)||N/A|
Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Incyte Corporation shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7842. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$467 million.
The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2.4 billion|
|Gross profit TTM||USD$890.4 million|
|Return on assets TTM||-3.77%|
|Return on equity TTM||-8.32%|
|Market capitalisation||USD$19.4 billion|
TTM: trailing 12 months
There are currently 5.3 million Incyte Corporation shares held short by investors – that's known as Incyte Corporation's "short interest". This figure is 2.9% down from 5.4 million last month.
There are a few different ways that this level of interest in shorting Incyte Corporation shares can be evaluated.
Incyte Corporation's "short interest ratio" (SIR) is the quantity of Incyte Corporation shares currently shorted divided by the average quantity of Incyte Corporation shares traded daily (recently around 1.1 million). Incyte Corporation's SIR currently stands at 4.8. In other words for every 100,000 Incyte Corporation shares traded daily on the market, roughly 4800 shares are currently held short.
However Incyte Corporation's short interest can also be evaluated against the total number of Incyte Corporation shares, or, against the total number of tradable Incyte Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Incyte Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Incyte Corporation shares in existence, roughly 20 shares are currently held short) or 0.0285% of the tradable shares (for every 100,000 tradable Incyte Corporation shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Incyte Corporation.
Find out more about how you can short Incyte Corporation stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Incyte Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 34.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Incyte Corporation's overall score of 34.23 (as at 08/01/2020) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Incyte Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 6.63/100
Incyte Corporation's environmental score of 6.63 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 27.6/100
Incyte Corporation's social score of 27.6 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.99/100
Incyte Corporation's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Incyte Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Incyte Corporation scored a 1 out of 5 for controversy – the highest score possible, reflecting that Incyte Corporation has managed to keep its nose clean.
|Total ESG score||34.23|
|Total ESG percentile||54.7|
|Environmental score percentile||8|
|Social score percentile||8|
|Governance score percentile||8|
|Level of controversy||1|
We're not expecting Incyte Corporation to pay a dividend over the next 12 months.
Incyte Corporation's shares were split on a 2:1 basis on 1 September 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $62.48 up to $110.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 1.0641. This would suggest that Incyte Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.